- Integration of CiNii Books functions for fiscal year 2025 has completed
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on November 26, 2025】Regarding the recording of “Research Data” and “Evidence Data”
- Incorporated Jxiv preprints from JaLC and adding coverage from NDL Search
A potential link between desmoglein 3 and epidermal growth factor receptor in oral squamous cell carcinoma and its effect on cetuximab treatment efficac
Bibliographic Information
- Published
- 2019-05
- Resource Type
- journal article
- Rights Information
-
- This is the peer reviewed version of the following article: Exp Dermatol. 2019 May;28(5):614-617, which has been published in final form at https://doi.org/10.1111/exd.13920. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
- DOI
-
- 10.1111/exd.13920
- Publisher
- Munksgaard
Search this article
Description
<jats:title>Abstract</jats:title><jats:p>Desmoglein (DSG) 3 is overexpressed in oral squamous cell carcinoma (OSCC). Epidermal growth factor receptor (EGFR) inhibitor cetuximab is widely used for OSCC treatment. Several evidences suggest a correlation between DSG3 and EGFR in epidermal keratinocytes. EGFR inhibition has been shown to enhance cell‐cell adhesion and induce terminal differentiation in epidermal cells. Thus, here we investigated the DSG3‐EGFR interaction in OSCC and its effect on cetuximab treatment. Cell lines established from the primary tumor and metastatic lymph nodes of four OSCC patients and three commercial OSCC cell lines were used for the experiments. Cells from metastatic lymph nodes of each patient expressed increased DSG3 and EGFR than cells from the primary tumor in the same patient. Cetuximab treatment increased DSG3 expression by up to 3.5‐fold in seven of the 11 cell lines. A high calcium concentration increased the expression of DSG3 and EGFR in a dose‐dependent manner. Strikingly, a high calcium‐associated DSG3 induction enhanced cetuximab efficacy by up to 23% increase in cetuximab‐low‐sensitive cell lines. Our findings also suggest a correlation between DSG3 and EGFR in OSCC, and this affects cetuximab treatment efficacy.</jats:p>
Journal
-
- Experimental dermatology
-
Experimental dermatology 28 (5), 614-617, 2019-05
Munksgaard
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1050850569144396160
-
- NII Article ID
- 120006949526
-
- NII Book ID
- AA10958794
-
- ISSN
- 16000625
- 09066705
-
- HANDLE
- 10130/5246
-
- PubMed
- 30907457
-
- Text Lang
- en
-
- Article Type
- journal article
-
- Data Source
-
- IRDB
- Crossref
- CiNii Articles
- KAKEN
- OpenAIRE
